$599

AZ to Invest $50B for US Manufacturing; Madrigal Secures $500M Credit for Pipeline Expansion 

Two cardiometabolic-related news items have been observed: AstraZeneca announced a $50B investment in US-based manufacturing facilities (view press release); and Madrigal Pharmaceuticals announced it secured $500M credit to primarily support its MASH pipeline expansion (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here